Manager, Pipeline and Portfolio Market Planning at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Bachelor's degree required. Advanced degree preferred (MBA, MSc, PhD, PharmD)
3-5 years of relevant professional experience
Demonstrated experience driving or supporting strategic planning within the biopharmaceutical or drug development industry
Strong project management and organizational capabilities with the ability to manage multiple priorities and timelines effectively
Exceptional communication and presentation skills, with the ability to proactively engage and influence cross-functional partners and leadership
Demonstrated analytical skills and experience with financial modeling
Ability to integrate complex data and insights from diverse sources into clear, actionable business narratives and recommendations
Previous market research experience preferred
Demonstrated success operating in a matrixed environment, collaborating across functions such as Clinical, Commercial, Finance, and Medical Affairs
Occasional travel required for corporate and industry events

Responsibilities

Co-lead and contribute to program-level strategy projects that optimize portfolio value, enhance program positioning, and inform critical business decisions
Manage and enhance competitive intelligence tools and reporting to monitor market dynamics and proactively inform program decisions
Partner cross-functionally to coordinate integrated planning workstreams, ensuring alignment of development, commercial, and financial perspectives
Maintain and update long-range revenue forecasts and portfolio valuations
Analyze market trends, clinical developments, and competitive landscape to identify opportunities, risks, and implications for Corcept’s pipeline strategy
Design and execute analytical projects to evaluate new development opportunities, including internal pipeline assets and external partnerships
Oversee contracting and budget management processes in partnership with Finance and Legal, ensuring alignment with corporate policies and strategic priorities
Lead and execute ad hoc strategic initiatives, providing analytical support and structured recommendations to enable informed decision-making
Contribute to international expansion planning by analyzing commercial, clinical and regulatory insights across key geographies
Uphold Corcept’s key principles of collaboration, embracing possibilities, following the data, and leading by doing

Skills

Financial Forecasting

Competitive Intelligence

Market Analysis

Revenue Forecasting

Portfolio Valuation

Business Case Development

Strategic Planning

Cross-Functional Collaboration

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free